Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
France
Department of Neurology, University Hospital of Besançon, Besançon, Bourgogne-Franche-Comté Medical Oncology Department, Eugène Marquis Centre, Rennes, Brittany Region Department of Neurology, Hopital de la Salpêtrière, Paris, Idf Neuro-oncology Department, La Timone Hospital, Marseille, Provence-Alpes-Côte d'Azur Region Department of Neurology, Hopital Saint louis (APHP), Paris